$AXON
AXON ENTERPRISE, INC.

2023 Q3 Form 10-Q Financial Statement

#000155837023013981 Filed on August 08, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2022 Q2
Revenue $413.6M $374.6M $285.6M
YoY Change 32.67% 31.16% 30.54%
Cost Of Revenue $158.3M $142.5M $111.7M
YoY Change 33.61% 27.62% 38.07%
Gross Profit $255.3M $232.1M $174.0M
YoY Change 32.09% 33.43% 26.13%
Gross Profit Margin 61.72% 61.96% 60.91%
Selling, General & Admin $123.3M $119.9M $95.01M
YoY Change 20.83% 26.23% -46.52%
% of Gross Profit 48.29% 51.66% 54.61%
Research & Development $76.88M $71.94M $57.55M
YoY Change 30.03% 25.01% 6.66%
% of Gross Profit 30.12% 30.99% 33.08%
Depreciation & Amortization $8.400M $7.480M $6.210M
YoY Change 35.35% 20.45% 44.69%
% of Gross Profit 3.29% 3.22% 3.57%
Operating Expenses $200.2M $191.9M $152.6M
YoY Change 24.21% 25.77% -34.14%
Operating Profit $55.11M $40.26M $21.41M
YoY Change 71.65% 88.03% -122.85%
Interest Expense $14.31M -$52.37M $47.03M
YoY Change -227.21% -211.36% 12.39%
% of Operating Profit 25.96% -130.08% 219.63%
Other Income/Expense, Net $3.852M -$62.03M
YoY Change
Pretax Income $69.42M -$12.11M $68.44M
YoY Change 232.84% -117.69% -232.01%
Income Tax $10.03M -$24.53M $17.48M
% Of Pretax Income 14.44% 25.53%
Net Earnings $59.40M $12.42M $50.96M
YoY Change 389.63% -75.63% -208.16%
Net Earnings / Revenue 14.36% 3.32% 17.84%
Basic Earnings Per Share $0.79 $0.17 $0.72
Diluted Earnings Per Share $0.78 $0.16 $705.0K
COMMON SHARES
Basic Shares Outstanding 74.76M 73.89M 71.01M
Diluted Shares Outstanding 75.95M 75.78M 72.28M

Balance Sheet

Concept 2023 Q3 2023 Q2 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $474.9M $539.0M $377.2M
YoY Change 159.52% 42.88% -42.43%
Cash & Equivalents $406.0M $474.2M $212.8M
Short-Term Investments $68.85M $64.80M $164.4M
Other Short-Term Assets $103.8M $101.6M $61.84M
YoY Change 52.53% 64.25% 36.04%
Inventory $260.1M $249.8M $154.3M
Prepaid Expenses
Receivables $703.4M $627.4M $576.4M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $2.258B $2.113B $1.170B
YoY Change 87.26% 80.6% 8.22%
LONG-TERM ASSETS
Property, Plant & Equipment $187.0M $179.1M $154.7M
YoY Change 13.89% 15.74% 29.02%
Goodwill $57.34M $57.74M
YoY Change 27.95%
Intangibles $20.32M $21.84M
YoY Change 55.87%
Long-Term Investments $240.3M $249.1M $306.6M
YoY Change -24.64% -18.75% 186.05%
Other Assets $194.5M $177.9M $204.7M
YoY Change 75.83% -13.09% 142.99%
Total Long-Term Assets $996.3M $964.8M $762.2M
YoY Change 23.81% 26.57% 70.92%
TOTAL ASSETS
Total Short-Term Assets $2.258B $2.113B $1.170B
Total Long-Term Assets $996.3M $964.8M $762.2M
Total Assets $3.254B $3.077B $1.932B
YoY Change 61.87% 59.28% 26.53%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $90.04M $72.99M $60.69M
YoY Change 79.38% 20.27% 680.26%
Accrued Expenses $146.9M $118.2M $94.56M
YoY Change 30.31% 24.96% 41.33%
Deferred Revenue $454.9M $412.2M
YoY Change 84.58%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $717.8M $625.2M $433.0M
YoY Change 66.35% 44.41% 58.67%
LONG-TERM LIABILITIES
Long-Term Debt $676.3M $675.5M $0.00
YoY Change
Other Long-Term Liabilities $2.960M $2.843M $305.4M
YoY Change -37.98% -99.07% 843.76%
Total Long-Term Liabilities $2.960M $2.843M $305.4M
YoY Change -37.98% -99.07% 843.76%
TOTAL LIABILITIES
Total Short-Term Liabilities $717.8M $625.2M $433.0M
Total Long-Term Liabilities $2.960M $2.843M $305.4M
Total Liabilities $1.733B $1.632B $738.4M
YoY Change 122.44% 121.08% 72.04%
SHAREHOLDERS EQUITY
Retained Earnings $374.0M $314.6M
YoY Change 64.14%
Common Stock $1.316B $1.293B
YoY Change 12.74%
Preferred Stock
YoY Change
Treasury Stock (at cost) $155.9M $155.9M
YoY Change 0.0%
Treasury Stock Shares
Shareholders Equity $1.521B $1.445B $1.194B
YoY Change
Total Liabilities & Shareholders Equity $3.254B $3.077B $1.932B
YoY Change 61.87% 59.28% 26.53%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2022 Q2
OPERATING ACTIVITIES
Net Income $59.40M $12.42M $50.96M
YoY Change 389.63% -75.63% -208.16%
Depreciation, Depletion And Amortization $8.400M $7.480M $6.210M
YoY Change 35.35% 20.45% 44.69%
Cash From Operating Activities $62.90M $42.66M $19.38M
YoY Change 53.79% 120.15% -43.3%
INVESTING ACTIVITIES
Capital Expenditures $14.40M $13.20M -$12.82M
YoY Change -199.59% -202.99% -5.86%
Acquisitions
YoY Change
Other Investing Activities -$107.6M $167.1M -$175.6M
YoY Change 21.23% -195.16% -286.47%
Cash From Investing Activities -$122.0M $153.9M -$188.4M
YoY Change 18.2% -181.69% -333.89%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -7.200M 14.26M -934.0K
YoY Change 9900.0% -1627.19% -71.37%
NET CHANGE
Cash From Operating Activities 62.90M 42.66M 19.38M
Cash From Investing Activities -122.0M 153.9M -188.4M
Cash From Financing Activities -7.200M 14.26M -934.0K
Net Change In Cash -66.30M 210.9M -170.0M
YoY Change 6.27% -224.03% -252.49%
FREE CASH FLOW
Cash From Operating Activities $62.90M $42.66M $19.38M
Capital Expenditures $14.40M $13.20M -$12.82M
Free Cash Flow $48.50M $29.46M $32.19M
YoY Change -12.39% -8.5% -32.64%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001069183
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
71474581
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
74763004
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-16391
dei Entity Registrant Name
EntityRegistrantName
Axon Enterprise, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
86-0741227
dei Entity Address Address Line1
EntityAddressAddressLine1
17800 North 85th Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Scottsdale
dei Entity Address State Or Province
EntityAddressStateOrProvince
AZ
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
85255
dei City Area Code
CityAreaCode
480
dei Local Phone Number
LocalPhoneNumber
991-0797
dei Security12b Title
Security12bTitle
Common Stock, $0.00001 Par Value
dei Trading Symbol
TradingSymbol
AXON
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
74759989
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
474203000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
353684000
CY2023Q2 us-gaap Marketable Securities
MarketableSecurities
64800000
CY2022Q4 us-gaap Marketable Securities
MarketableSecurities
39240000
CY2023Q2 us-gaap Short Term Investments
ShortTermInvestments
594942000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
581769000
CY2023Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1950000
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2176000
CY2023Q2 us-gaap Accounts Notes And Loans Receivable Net Current
AccountsNotesAndLoansReceivableNetCurrent
372060000
CY2022Q4 us-gaap Accounts Notes And Loans Receivable Net Current
AccountsNotesAndLoansReceivableNetCurrent
358190000
CY2023Q2 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
255306000
CY2022Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
196902000
CY2023Q2 us-gaap Inventory Net
InventoryNet
249767000
CY2022Q4 us-gaap Inventory Net
InventoryNet
202471000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
101572000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
73022000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
2112650000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
1805278000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
179096000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
169843000
CY2023Q2 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
198581000
CY2022Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
156866000
CY2023Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
21837000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
12158000
CY2023Q2 us-gaap Goodwill
Goodwill
57741000
CY2022Q4 us-gaap Goodwill
Goodwill
44983000
CY2023Q2 us-gaap Long Term Investments
LongTermInvestments
15481000
CY2022Q4 us-gaap Long Term Investments
LongTermInvestments
156207000
CY2023Q2 us-gaap Long Term Accounts Notes And Loans Receivable Net Noncurrent
LongTermAccountsNotesAndLoansReceivableNetNoncurrent
5278000
CY2022Q4 us-gaap Long Term Accounts Notes And Loans Receivable Net Noncurrent
LongTermAccountsNotesAndLoansReceivableNetNoncurrent
5210000
CY2023Q2 us-gaap Contract With Customer Asset Net Noncurrent
ContractWithCustomerAssetNetNoncurrent
75200000
CY2022Q4 us-gaap Contract With Customer Asset Net Noncurrent
ContractWithCustomerAssetNetNoncurrent
45170000
CY2023Q2 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
233637000
CY2022Q4 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
296563000
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
177903000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
159616000
CY2023Q2 us-gaap Assets
Assets
3077404000
CY2022Q4 us-gaap Assets
Assets
2851894000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
72989000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
59918000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
118162000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
155934000
CY2023Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
412212000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
360037000
CY2023Q2 axon Customer Deposit Current
CustomerDepositCurrent
14517000
CY2022Q4 axon Customer Deposit Current
CustomerDepositCurrent
20399000
CY2023Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
7359000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
6358000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
625239000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
602646000
CY2023Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
265458000
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
248003000
CY2023Q2 us-gaap Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
17812000
CY2022Q4 us-gaap Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
10745000
CY2023Q2 us-gaap Deferred Compensation Liability Classified Noncurrent
DeferredCompensationLiabilityClassifiedNoncurrent
8767000
CY2022Q4 us-gaap Deferred Compensation Liability Classified Noncurrent
DeferredCompensationLiabilityClassifiedNoncurrent
6285000
CY2023Q2 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
2782000
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
1000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
33987000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
37143000
CY2023Q2 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
675518000
CY2022Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
673967000
CY2023Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2843000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4613000
CY2023Q2 us-gaap Liabilities
Liabilities
1632406000
CY2022Q4 us-gaap Liabilities
Liabilities
1583403000
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
74763004
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
71474581
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
1000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1293089000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1174594000
CY2023Q2 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
20220227
CY2022Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
20220227
CY2023Q2 us-gaap Treasury Stock Value
TreasuryStockValue
155947000
CY2022Q4 us-gaap Treasury Stock Value
TreasuryStockValue
155947000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
314581000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
257022000
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-6726000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-7179000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
1444998000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1268491000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3077404000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2851894000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
374605000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
285613000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
717648000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
542039000
CY2023Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
142484000
CY2022Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
111650000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
281425000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
212337000
CY2023Q2 us-gaap Gross Profit
GrossProfit
232121000
CY2022Q2 us-gaap Gross Profit
GrossProfit
173963000
us-gaap Gross Profit
GrossProfit
436223000
us-gaap Gross Profit
GrossProfit
329702000
CY2023Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
119922000
CY2022Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
95005000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
236489000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
185134000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
71940000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
57547000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
142867000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
105963000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
191862000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
152552000
us-gaap Operating Expenses
OperatingExpenses
379356000
us-gaap Operating Expenses
OperatingExpenses
291097000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
40259000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
21411000
us-gaap Operating Income Loss
OperatingIncomeLoss
56867000
us-gaap Operating Income Loss
OperatingIncomeLoss
38605000
CY2023Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-52368000
CY2022Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
47026000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-27092000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
102325000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-12109000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
68437000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
29775000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
140930000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-24529000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
17475000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-27784000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
35097000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
12420000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
50962000
us-gaap Net Income Loss
NetIncomeLoss
57559000
us-gaap Net Income Loss
NetIncomeLoss
105833000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.17
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.72
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.78
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.49
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.16
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.71
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.77
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.46
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
74224000
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
71040000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
73435000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
70995000
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
75780000
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
72283000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
74834000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
72316000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
12420000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
50962000
us-gaap Net Income Loss
NetIncomeLoss
57559000
us-gaap Net Income Loss
NetIncomeLoss
105833000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-557000
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2166000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1119000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-3238000
CY2023Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-850000
CY2022Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-161000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-666000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-650000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
11013000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
48635000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
58012000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
101945000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1268491000
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
33650000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
-34841000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
54346000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
34350000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
45139000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1860000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1402995000
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
61156000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
-62214000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
157000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
31891000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
12420000
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1407000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
1444998000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
1047849000
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
-70000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
-1388000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
25088000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
54871000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1561000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
1124789000
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
-4000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
-931000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
21162000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
50962000
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-2327000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
1193651000
us-gaap Profit Loss
ProfitLoss
57559000
us-gaap Profit Loss
ProfitLoss
105833000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
14169000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
11965000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1531000
axon Payment Of Coupon Interest
PaymentOfCouponInterest
1725000
us-gaap Goodwill Purchase Accounting Adjustments
GoodwillPurchaseAccountingAdjustments
58000
us-gaap Gain Loss On Disposition Of Intangible Assets
GainLossOnDispositionOfIntangibleAssets
-18000
us-gaap Gain Loss On Disposition Of Intangible Assets
GainLossOnDispositionOfIntangibleAssets
-48000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-162000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-189000
us-gaap Gain Loss On Investments
GainLossOnInvestments
-46342000
us-gaap Gain Loss On Investments
GainLossOnInvestments
103836000
axon Gain Loss On Insurance Recoveries
GainLossOnInsuranceRecoveries
789000
us-gaap Share Based Compensation
ShareBasedCompensation
66241000
us-gaap Share Based Compensation
ShareBasedCompensation
46250000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-37605000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
26050000
axon Provision For Unrecognized Tax Benefits
ProvisionForUnrecognizedTaxBenefits
2867000
axon Provision For Unrecognized Tax Benefits
ProvisionForUnrecognizedTaxBenefits
3895000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
-8036000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
301000
axon Non Cash Lease Expense
NonCashLeaseExpense
2978000
axon Non Cash Lease Expense
NonCashLeaseExpense
3279000
axon Credit Loss Reserve
CreditLossReserve
341000
axon Credit Loss Reserve
CreditLossReserve
183000
us-gaap Increase Decrease In Accounts And Notes Receivable
IncreaseDecreaseInAccountsAndNotesReceivable
102205000
us-gaap Increase Decrease In Accounts And Notes Receivable
IncreaseDecreaseInAccountsAndNotesReceivable
80247000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
43585000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
47109000
axon Increase Decrease In Prepaid Expense And Other Current Assets
IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets
49290000
axon Increase Decrease In Prepaid Expense And Other Current Assets
IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets
2688000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-35976000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
24569000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
69886000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
74600000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13667000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
63340000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
246049000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
108240000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
381082000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
9473000
axon Payments On Exercise Of Warrants Of Strategic Investment
PaymentsOnExerciseOfWarrantsOfStrategicInvestment
6555000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
21650000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
29847000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
3000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
91000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
187000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
104000
axon Payments To Acquire Equity Securities Without Readily Determinable Fair Value
PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValue
10917000
axon Payments To Acquire Equity Securities Without Readily Determinable Fair Value
PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValue
61500000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
21026000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
2104000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
81256000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-198786000
axon Net Proceeds From Equity Offering
NetProceedsFromEquityOffering
94806000
axon Net Proceeds From Equity Offering
NetProceedsFromEquityOffering
-74000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
54503000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
97055000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
2319000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
52254000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2393000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
806000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-3910000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
120649000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-141749000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
355552000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
356438000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
476201000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
214689000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
474203000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
212815000
CY2023Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
1998000
CY2022Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
1874000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
476201000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
214689000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
25052000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
2289000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
750000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2009000
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
12420000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
50962000
us-gaap Net Income Loss
NetIncomeLoss
57559000
us-gaap Net Income Loss
NetIncomeLoss
105833000
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
74224000
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
71040000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
73435000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
70995000
CY2023Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1556000
CY2022Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1243000
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1399000
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1321000
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
75780000
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
72283000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
74834000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
72316000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.17
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.72
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.78
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.49
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.16
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.71
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.77
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.46
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6163000
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2991000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6169000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2912000
axon Warranty Period After Purchase Of Product
WarrantyPeriodAfterPurchaseOfProduct
P1Y
CY2022Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
811000
CY2021Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
2822000
us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
514000
us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
1574000
us-gaap Product Warranty Accrual Preexisting Increase Decrease
ProductWarrantyAccrualPreexistingIncreaseDecrease
3143000
us-gaap Product Warranty Accrual Preexisting Increase Decrease
ProductWarrantyAccrualPreexistingIncreaseDecrease
380000
CY2023Q2 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
3440000
CY2022Q2 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1628000
CY2023Q2 us-gaap Cash Surrender Value Fair Value Disclosure
CashSurrenderValueFairValueDisclosure
5200000
CY2022Q4 us-gaap Cash Surrender Value Fair Value Disclosure
CashSurrenderValueFairValueDisclosure
4300000
axon Investments In Number Of Affiliates
InvestmentsInNumberOfAffiliates
8
CY2023Q2 axon Debt Instrument Principal Amount Denomination For Fair Value Calculation
DebtInstrumentPrincipalAmountDenominationForFairValueCalculation
1000
CY2023Q2 us-gaap Restricted Cash
RestrictedCash
2000000.0
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
1900000
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Reclassification of Prior Year Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications are not material and had no effect on the reported results of operations.</p>
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
374605000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
285613000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
717648000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
542039000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
374605000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
285613000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
717648000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
542039000
CY2023Q2 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
330506000
CY2023Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
677670000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
221765000
CY2023Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
412212000
CY2023Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
265458000
CY2023Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
677670000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
360037000
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
248003000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
608040000
CY2023Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
412212000
CY2023Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
265458000
CY2023Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
677670000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
360037000
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
248003000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
608040000
CY2023Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
5200000000
CY2023Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1176854000
CY2023Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
76000
CY2023Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
27504000
axon Equity Securities Without Readily Determinable Fair Value Purchases
EquitySecuritiesWithoutReadilyDeterminableFairValuePurchases
140679000
CY2023Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1149426000
CY2023Q2 axon Cash Cash Equivalent And Investments Amortized Cost
CashCashEquivalentAndInvestmentsAmortizedCost
474203000
CY2023Q2 us-gaap Marketable Securities
MarketableSecurities
64800000
CY2023Q2 axon Short Term Investment
ShortTermInvestment
594942000
CY2023Q2 axon Long Term Investment
LongTermInvestment
15481000
us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
391700000
us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
391700000
CY2023Q2 axon Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Unrealized Losses
AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerUnrealizedLosses
21300000
CY2023Q2 axon Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Gross Unrealized Losses
AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerGrossUnrealizedLosses
500000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1183222000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
57000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
52379000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1130900000
CY2022Q4 axon Cash Cash Equivalent And Investments Amortized Cost
CashCashEquivalentAndInvestmentsAmortizedCost
353684000
CY2022Q4 us-gaap Marketable Securities
MarketableSecurities
39240000
CY2022Q4 axon Short Term Investment
ShortTermInvestment
581769000
CY2022Q4 axon Long Term Investment
LongTermInvestment
156207000
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
3630000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
341000
us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
506000
CY2023Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
3465000
CY2023Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1950000
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2176000
CY2023Q2 us-gaap Contract With Customer Asset Accumulated Allowance For Credit Loss
ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
1447000
CY2022Q4 us-gaap Contract With Customer Asset Accumulated Allowance For Credit Loss
ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
1360000
CY2023Q2 us-gaap Allowance For Doubtful Accounts Receivable Noncurrent
AllowanceForDoubtfulAccountsReceivableNoncurrent
68000
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Noncurrent
AllowanceForDoubtfulAccountsReceivableNoncurrent
94000
CY2023Q2 axon Allowance For Expected Credit Losses On Customer Receivables
AllowanceForExpectedCreditLossesOnCustomerReceivables
3465000
CY2022Q4 axon Allowance For Expected Credit Losses On Customer Receivables
AllowanceForExpectedCreditLossesOnCustomerReceivables
3630000
CY2023Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
96467000
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
72740000
CY2023Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
153300000
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
129731000
CY2023Q2 us-gaap Inventory Net
InventoryNet
249767000
CY2022Q4 us-gaap Inventory Net
InventoryNet
202471000
CY2023Q1 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
296563000
CY2022Q1 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
154452000
CY2023Q2 axon Equity Securities Without Readily Determinable Fair Value Purchases
EquitySecuritiesWithoutReadilyDeterminableFairValuePurchases
10917000
CY2022Q2 axon Equity Securities Without Readily Determinable Fair Value Purchases
EquitySecuritiesWithoutReadilyDeterminableFairValuePurchases
61000000
CY2023Q2 axon Equity Securities Without Readily Determinable Fair Value Downward Price Adjustment And Impairment Annual Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAndImpairmentAnnualAmount
73843000
CY2022Q2 axon Equity Securities Without Readily Determinable Fair Value Downward Price Adjustment And Impairment Annual Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAndImpairmentAnnualAmount
391000
CY2022Q2 axon Equity Securities Without Readily Determinable Fair Value Exercises
EquitySecuritiesWithoutReadilyDeterminableFairValueExercises
66630000
CY2023Q2 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
233637000
CY2022Q2 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
281691000
CY2022Q4 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
296563000
CY2021Q4 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
83520000
axon Equity Securities Without Readily Determinable Fair Value Purchases
EquitySecuritiesWithoutReadilyDeterminableFairValuePurchases
10917000
axon Equity Securities Without Readily Determinable Fair Value Purchases
EquitySecuritiesWithoutReadilyDeterminableFairValuePurchases
61500000
us-gaap Equity Securities Without Readily Determinable Fair Value Upward Price Adjustment Annual Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount
0
us-gaap Equity Securities Without Readily Determinable Fair Value Upward Price Adjustment Annual Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount
70432000
axon Equity Securities Without Readily Determinable Fair Value Downward Price Adjustment And Impairment Annual Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAndImpairmentAnnualAmount
73843000
axon Equity Securities Without Readily Determinable Fair Value Downward Price Adjustment And Impairment Annual Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAndImpairmentAnnualAmount
391000
axon Equity Securities Without Readily Determinable Fair Value Exercises
EquitySecuritiesWithoutReadilyDeterminableFairValueExercises
66630000
CY2023Q2 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
233637000
CY2022Q2 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
281691000
axon Equity Securities Without Readily Determinable Fair Value Gain On Sale Of Securities
EquitySecuritiesWithoutReadilyDeterminableFairValueGainOnSaleOfSecurities
12312000
us-gaap Equity Securities Without Readily Determinable Fair Value Upward Price Adjustment Annual Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount
103890000
axon Equity Securities Without Readily Determinable Fair Value Downward Price Adjustment And Impairment Annual Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAndImpairmentAnnualAmount
75328000
axon Equity Securities Without Readily Determinable Fair Value Exercises
EquitySecuritiesWithoutReadilyDeterminableFairValueExercises
66630000
axon Equity Securities Without Readily Determinable Fair Value Sales
EquitySecuritiesWithoutReadilyDeterminableFairValueSales
14546000
CY2023Q2 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
233637000
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
60778000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
97882000
CY2023Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
6370000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3861000
CY2023Q2 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
3440000
CY2022Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
811000
CY2023Q2 us-gaap Taxes Payable Current
TaxesPayableCurrent
5825000
CY2022Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
13559000
CY2023Q2 axon Accrued Inventory In Transit Current
AccruedInventoryInTransitCurrent
13812000
CY2022Q4 axon Accrued Inventory In Transit Current
AccruedInventoryInTransitCurrent
10548000
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
27937000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
29273000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
118162000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
155934000
CY2023Q2 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
195800000
CY2023Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
24300000
CY2023Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
24300000
us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
5300000
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.933
us-gaap Effective Income Tax Rate Reconciliation Tax Contingencies
EffectiveIncomeTaxRateReconciliationTaxContingencies
0.160
axon Effective Income Tax Rate Reconciliation Deduction Stockbased Compensation
EffectiveIncomeTaxRateReconciliationDeductionStockbasedCompensation
33900000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
246000000.0
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
0
CY2023Q2 us-gaap Share Based Compensation
ShareBasedCompensation
31891000
CY2022Q2 us-gaap Share Based Compensation
ShareBasedCompensation
21162000
us-gaap Share Based Compensation
ShareBasedCompensation
66241000
us-gaap Share Based Compensation
ShareBasedCompensation
46250000
axon Debt Instrument Covenant Consolidated Leverage Ratio
DebtInstrumentCovenantConsolidatedLeverageRatio
0.45
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
374605000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
285613000
CY2023Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
142484000
CY2022Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
111650000
CY2023Q2 us-gaap Gross Profit
GrossProfit
232121000
CY2022Q2 us-gaap Gross Profit
GrossProfit
173963000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
71940000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
57547000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
717648000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
542039000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
281425000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
212337000
us-gaap Gross Profit
GrossProfit
436223000
us-gaap Gross Profit
GrossProfit
329702000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
142867000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
105963000

Files In Submission

Name View Source Status
0001558370-23-013981-index-headers.html Edgar Link pending
0001558370-23-013981-index.html Edgar Link pending
0001558370-23-013981.txt Edgar Link pending
0001558370-23-013981-xbrl.zip Edgar Link pending
axon-20230630.xsd Edgar Link pending
axon-20230630x10q.htm Edgar Link pending
axon-20230630xex31d1.htm Edgar Link pending
axon-20230630xex31d2.htm Edgar Link pending
axon-20230630xex32d1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
axon-20230630_cal.xml Edgar Link unprocessable
axon-20230630_def.xml Edgar Link unprocessable
axon-20230630_lab.xml Edgar Link unprocessable
axon-20230630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
axon-20230630x10q_htm.xml Edgar Link completed
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending